ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Natera, Genentech Initiate Phase III Trial Using Signatera americanpharmaceuticalreview
March 17, 2021Natera announced the first patient has been screened in a new phase III clinical trial that uses its tumor-informed, personalized molecular residual disease (MRD) test, Signatera, as a companion diagnostic to identify muscle-invasive urothelial ...
Pharma Sources Insight January 2025
